Chief Development Officer — Renal & Rare Diseases

Hlx Life Sciences; United States; On-site; USD 450,000 - 900,000; Full time

Job summary

HLX Life Sciences is seeking a Chief Development Officer to lead Clinical Development, Clinical Operations and Regulatory Affairs for a renal and rare disease biotech in the clinical stage.

Reporting to the CEO and Board, the CDO will shape the development strategy, advance the pipeline through milestones and build high-performing teams across external partners and internal functions.

Qualifications

• Significant leadership experience in biotech/pharmaceutical clinical development.
• Experience overseeing Clinical Development, Clinical Operations and Regulatory functions.
• Strong knowledge of rare disease development and related complexities.
• Experience advancing assets through clinical and regulatory milestones.
• Ability to operate strategically at executive level while staying close to execution.
• Strong cross-functional leadership and communication skills.
• Renal/nephrology development experience desired.
• Previous CDO/Head of Development/SVP or equivalent leadership preferred.

Responsibilities

• Provide strategic leadership across Clinical Development, Clinical Operations and Regulatory.
• Own and execute overall clinical and regulatory development strategy.
• Oversee design and delivery of clinical programs with study/execution excellence.
• Lead interactions with regulators including the FDA.
• Partner with CEO, Board on pipeline and corporate strategy.
• Build and lead development teams and external partners.
• Establish relationships with investigators and KOLs.
• Support future pipeline expansion and broader development opportunities.

Skills

Leadership in clinical development

Regulatory affairs leadership

Cross-functional leadership

Strategic planning

Stakeholder engagement

Education

MD or PhD welcomed

Job description

HLX Life Sciences is seeking a Chief Development Officer to lead Clinical Development, Clinical Operations and Regulatory Affairs for a renal and rare disease biotech in the clinical stage.

Reporting to the CEO and Board, the CDO will shape the development strategy, advance the pipeline through milestones and build high-performing teams across external partners and internal functions.